Your insult aside, one doesn't need to understand the rabbit paper, as we already know the FDA saw this data over a year ago and wasn't swayed by it. Will the very limited Indian results (with a different product than RDGL seeks to trial in USA) compensate for the poor rabbit results? Time will tell.
Market Data 
Markets 
